Uploaded January 2023 | Updated November 2026, 2 days ago
Air date: Wednesday, January 11, 2023, 2PM
Description: NIH Director’s Wednesday Afternoon Lecture Series [WALS]
When technology is properly created and applied it can be of tremendous benefit to people with disabilities. People with disabilities along with their allies know better than any other how being involved in the planning from day one is critical to a successfully accessible product, regardless of how many years in the future it lies. Dr. Cooper will present on technologies and research that he and members of the team at the Human Engineering Research Laboratories are working on ranging from Apps, cushions, homes, robots, and wheelchairs. Dr. Cooper will also speak about innovative education programs to build research and development capacity among people with disabilities and veterans.
Dr. Rory Cooper is the founding director at the Human Engineering Research Laboratories, a VA Rehabilitation Research and Development Center of Excellence in partnership with Pitt. Also, he serves as co-director of the NSF Quality of Life Technology Engineering Research Center, a joint Pitt-Carnegie Mellon University venture.
For more information go to oir.nih.gov/wals
Author: Rory Cooper, Ph.D., University of Pittsburgh
Permanent link: videocast.nih.gov/watch=46052
Air date: Wednesday, January 11, 2023, 2PM
Description: NIH Director’s Wednesday Afternoon Lecture Series [WALS]
When technology is properly created and applied it can be of tremendous benefit to people with disabilities. People with disabilities along with their allies know better than any other how being involved in the planning from day one is critical to a successfully accessible product, regardless of how many years in the future it lies. Dr. Cooper will present on technologies and research that he and members of the team at the Human Engineering Research Laboratories are working on ranging from Apps, cushions, homes, robots, and wheelchairs. Dr. Cooper will also speak about innovative education programs to build research and development capacity among people with disabilities and veterans.
Dr. Rory Cooper is the founding director at the Human Engineering Research Laboratories, a VA Rehabilitation Research and Development Center of Excellence in partnership with Pitt. Also, he serves as co-director of the NSF Quality of Life Technology Engineering Research Center, a joint Pitt-Carnegie Mellon University venture.
For more information go to oir.nih.gov/wals
Author: Rory Cooper, Ph.D., University of Pittsburgh
Permanent link: videocast.nih.gov/watch=46052



![Regenerating and Rejuvenating Aged Tissues by Targeting a Gerozyme
Air date: Wednesday, February 1, 2023, 2PM
Description: NIH Director’s Wednesday Afternoon Lecture [WALS]
See https://en.wikipedia.org/wiki/Helen_Blau
For more information go to https://oir.nih.gov/wals
Author: Helen Blau, Ph.D., Stanford Medicine
Permanent link: https://videocast.nih.gov/watch=46058 Regenerating and Rejuvenating Aged Tissues by Targeting a Gerozyme](https://i.ytimg.com/vi/rPVoQesTplU/mqdefault.jpg)


![Overcoming the Undruggable Nature of the Most Common Human Oncogene K-Ras
Air date: Wednesday, March 8, 2023, 2PM
Description: NIH Directors WALS Lecture [WALS]
Kevan Shokat is a chemist who discovers drugs against some of the most common drivers of human cancers. He is best known for targeting a mutation that drives more than 1 in 10 lung cancers, opening up a new arena of cancer treatment discovery. The target, K-Ras, is the most common driver of cancer, and was considered “undruggable” by most cancer researchers after 40 years of failed attempts to block its function. Dr. Shokat’s discovery of a K-Ras blocker broke through this decades-old barrier and threw open the doors to a new class of cancer treatments. Lecture summary: 1. To understand the chemical, biochemical and cellular challenges to identifying a drug to target K-Ras mutant tumors 2. To learn how to discover drugs which only target oncogenes in cancer cells while sparing signaling in the rest of the body using covalent chemistry. 3. To learn about new approaches for combination therapy in cancer including re-activation of the tumor suppressor p53 and engaging the immune cells to overcome resistance to targeted therapies.
https://cancer.ucsf.edu/people/shokat.kevan
For more information go to https://oir.nih.gov/wals
Author: Kevan Shokat, Ph.D., University of California, Berkeley
Permanent link: https://videocast.nih.gov/watch=46070 Overcoming the Undruggable Nature of the Most Common Human Oncogene K-Ras](https://i.ytimg.com/vi/rtR3yl5U4yk/mqdefault.jpg)



